ILMN · CIK 1110803
What Illumina, Inc. told the SEC could break it.
Illumina's disclosures are dominated by geopolitics and supply. Its addition to China's Unreliable Entity List early in 2025 cut Greater China revenue by $65 million, and tariffs and trade restrictions raised costs (about a one-point gross-margin drag), with risk of having to curtail or exit China operations. On the supply side, its complex sequencing products require customized, precision-manufactured sub-assemblies and components available from only a limited number of sources — in some cases a single source — so a delivery delay or quality failure could halt manufacturing, which it concentrates in just a few sites (California, Wisconsin, the UK and Singapore). It also flags softer demand from 2025 macro headwinds and reductions in U.S. NIH research funding that weigh on customers' instrument purchasing.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- China Unreliable Entity List, tariffs and export/trade restrictionshigh
Illumina's inclusion on China's Unreliable Entity List in early 2025 cut Greater China revenue by $65M (region revenue $243M); tariffs/trade restrictions also raised costs (a ~1pt gross-margin drag), with risk of curtailing or exiting China operations.
“Total revenue in 2025 was impacted, across all products and services, by a decrease in revenue in our Greater China region of $65 million , primarily due to our inclusion on the List of Unreliable Entities in the beginning of the year. ... Changes in tariffs, trade restrictions, and customs or export/import regulations have impacted, and we expect will continue to impact, our business by increasing costs and administrative burdens, disrupting cross-border flows, and affecting customer demand.”
Sole-source dependency
- single-source precision sub-assemblies, components and materialshigh
Illumina's complex sequencing products require customized, precision-manufactured sub-assemblies, components and materials available from a limited number of sources — and in some cases only a single source — so delivery delays or quality failures could halt manufacturing.
“The complex nature of our products requires customized, precision-manufactured sub-assemblies, components, and materials that currently are available from a limited number of sources, and, in the case of some sub-assemblies, components, and materials, from only a single source. If deliveries from these vendors are delayed or interrupted for any reason, or if we are otherwise unable to secure a sufficient supply, we may not be able to obtain these sub-assemblies, components, or materials on a timely basis or in sufficient quantities or at satisfactory qualities.”
SEC filing →As of 2026
Geographic concentration
- limited manufacturing locations (California, Wisconsin, UK, Singapore)medium
Illumina manufactures in a limited number of locations — San Diego/SF Bay Area (CA, earthquake/wildfire-prone), Madison (WI), Cambridge (UK) and Singapore — so a catastrophic event or component shortage at one site could disrupt production.
“We currently manufacture in a limited number of locations. Our manufacturing facilities are located in San Diego and the San Francisco Bay Area in California; Madison, Wisconsin; Cambridge, United Kingdom; and Singapore. These areas are subject to natural disasters such as earthquakes, wildfires, or floods.”
SEC filing →As of 2026
Other disclosures
- NIH funding cuts and sequencing-demand softnessmedium
2025 headwinds — tariffs, inflation, FX, China competition, Russia sanctions and reductions in U.S. NIH research funding — weighed on Illumina and its customers' instrument-purchasing behavior amid capital/cash constraints.
“Throughout 2025, we experienced several headwinds including macroeconomic factors such as tariffs, inflation, exchange rate fluctuations and concerns about an economic downturn, competitive challenges in our China region, the sanctions imposed on Russia as a result of the armed conflict between Russia and Ukraine, and reductions in the U.S. government's funding of the NIH, all of which have impacted both Illumina directly and our customers' behavior.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Illumina, Inc., or Illumina, which supplies us with instruments, laboratory reagents and consumab”
Cited →“we rely on Illumina as the sole supplier of the next generation sequencers and associated reagents we use to perform our genetic tests and as the sole provider of maintenance and repair services for these sequencers”
Cited →“We rely on Illumina, Inc. as a sole supplier for our next-generation sequencers and associated reagents, Madison Industries as a sole supplier of blood collection tubes, and Twist Bioscience Corporation as a sole supplier of DNA panels.”
Cited →“our molecular diagnostics tests are currently only validated to perform on Illumina's sequencing platform; in addition, Illumina is currently the sole supplier of our sequencers and related reagents for Panorama, Horizon, Signatera and Prospera, along with certain hardware and software, pursuant to a supply agreement that expires in August 2033.”
Cited →“We rely on a limited number of suppliers, including Illumina, Inc., Life Technologies Corporation, Twist Biosciences Corporation, Path-Tec LLC and Agilent Technologies.”
Cited →“our OncoExTra test is currently only validated to be performed on Illumina's sequencing platform, and the MRD and MCED tests we launched in 2025 will similarly utilize this platform.”
Cited →“We rely on a limited number of suppliers or, in some cases, sole suppliers, including Illumina Inc., or Illumina, for certain sequencers, reagents, blood tubes and other equipment, software, instruments and materials that we use in our laboratory operations.”
Cited →“We rely on Illumina, Inc. (“Illumina”) as the sole supplier of NGS instruments and the associated sequencing reagent kits for our solutions. Illumina is also the sole provider of maintenance and repair services for these sequencing instruments.”
Cited →“We rely on a limited number of suppliers or, in some cases, sole suppliers, including Illumina Inc., or Illumina, for certain sequencers, reagents, blood tubes and other equipment, instruments and materials that we use in our laboratory operations. Purchases from this supplier accounted for approximately 33%, 39% and 33% of total vendor payments for the years ended December 31, 2025, 2024 and 2023, respectively.”
Cited →“we rely on Illumina as the sole supplier of sequencers and various associated reagents, and as the sole provider of maintenance and repair services for these sequencers.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch